iX Biopharma Ltd. (SG:42C) has released an update.
iX Biopharma Ltd is developing a new sublingual semaglutide wafer, iXB 401, aimed at treating diabetes and obesity through its WaferlogiX technology, with plans to out-license in China. The product is anticipated to offer better absorption and efficacy compared to existing semaglutide medications and capitalize on expiring patents by 2026. This strategic move aligns with the booming GLP-1 drug market, expected to be worth US$100 billion by 2030.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
